Osr1-mediated mesothelial transition of liver mesenchymal cells exacerbates fibrotic liver damage
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.02.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Xinxin Nian und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, Ministry of Education Key Laboratory of Cell Proliferation and Differentiation, Beijing Key Lab…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Disease Models, Animal, Transcription Factors, Hepatic Stellate Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, NSFC.
Abstract (Originalsprache)
In chronic liver diseases, hepatic stellate cells (HSCs) are induced to form the myofibroblasts responsible for scar formation, leading to liver fibrosis and cirrhosis. Here, single-cell RNA sequencing with in vivo lineage tracing in nonalcoholic steatohepatitis (NASH) model mice reveals a subpopulation of HSCs transitioning back to a state resembling their developmental precursors, mesothelial cells (MCs), after liver injury. These damage-associated intermediates between HSCs and MCs (DIHMs) can be traced with a dual recombinase system by labeling Krt19-expressing cells within prelabeled Pdgfrb+ HSCs, and DIHMs highly express inflammation- and fibrosis-associated genes. Cre and Dre-inducible depletion of DIHMs by administering diphtheria toxin reduces liver fibrosis and alleviates liver damage in NASH model mice. Importantly, knockdown of Osr1, a zinc finger transcription factor of the OSR gene family, can block DIHM induction in vitro. Conditional knockout Osr1 in Pdgfrb-expressing mesenchymal cells in NASH model mice can reduce liver fibrosis in vivo. Our study collectively uncovers an injury-induced developmental reversion process wherein HSCs undergo what we call a mesenchymal-to-mesothelial transition, which can be targeted to develop interventions to treat chronic liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural and Biomimetic Drugs, Ministry of Education Key Laboratory of Cell Proliferation and Differentiation, Beijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular…
- Department of Biochemistry and Biophysics, Peking University Health Science Center, Beijing 100191, P.R. China.
- State Key Laboratory of Organ Failure Research, Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
- New Cornerstone Science Laboratory, State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of…
- Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing 100044, China.
Förderung
- National Key Research and Development Program of China
- NSFC
Zitieren
APA
Nian, X., Lin, P., Bai, Y., Yu, D., Yang, X., Zhou, B., Gao, J., & Zhao, Y. (2024). Osr1-mediated mesothelial transition of liver mesenchymal cells exacerbates fibrotic liver damage. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.02.024
Vancouver
Nian X, Lin P, Bai Y, Yu D, Yang X, Zhou B, et al. Osr1-mediated mesothelial transition of liver mesenchymal cells exacerbates fibrotic liver damage. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.02.024
BibTeX
@article{Nian2024,
author = {Nian, Xinxin and Lin, Pengyan and Bai, Yunfei and Yu, Donglin and Yang, Xinyan and Zhou, Bin and Gao, Jie and Zhao, Yang},
title = {Osr1-mediated mesothelial transition of liver mesenchymal cells exacerbates fibrotic liver damage},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.02.024}
}
EUVIMED